Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines
NCT04143854
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Lateral Canthal Lines
Interventions
DRUG:
MBA-P01(Botulinum toxin A)
DRUG:
Placebo
Sponsor
Medy-Tox